Erschienen in:
01.03.2013 | Current Opinion
LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?
verfasst von:
Joost Besseling, Julian van Capelleveen, John J. P. Kastelein, G. Kees Hovingh
Erschienen in:
Drugs
|
Ausgabe 4/2013
Einloggen, um Zugang zu erhalten
Abstract
It is widely recognised that low-density lipoprotein cholesterol (LDL-C) is one of the most important and modifiable risk factors for cardiovascular disease (CVD). Statins (HMG-CoA reductase inhibitors) have consistently been shown to decrease both LDL-C and CVD risk in almost all patient categories, with the exception of heart and kidney failure as well as advanced aortic stenosis. As a consequence, statins have become the cornerstone in current prevention guidelines. In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered. Guidelines provide different LDL-C levels to strive for, depending on the CVD risk. In this review, we describe the rationale for these LDL-C targets and how these goals might be reached by current and future therapies.